KEVIN A ROTH, MD
Medical Practice at 19 St, Birmingham, AL
License number
Alabama L-2358DP
Category
Medical Practice
Type
Neuropathology
Address
Address
619 19Th St SOUTH, Birmingham, AL 35233
Phone
(205) 934-6600
(205) 731-9701
(205) 731-9701
Organization information
See more information about KEVIN A ROTH at bizstanding.comUab Hospital - Kevin A Roth MD
1802 6 Ave S, Birmingham, AL 35233
Categories:
Pathology Physicians & Surgeons
Site:
Phone:
(205) 934-9999 (Phone)
Professional information
See more information about KEVIN A ROTH at trustoria.com
Kevin Roth, Birmingham AL
Kevin Roth, Birmingham AL
Work:
Birmingham Va Medical Center
700 19Th St S, Birmingham, AL 35233
700 19Th St S, Birmingham, AL 35233
Dr. Kevin A Roth, Birmingham AL - MD (Doctor of Medicine)
Dr. Kevin A Roth, Birmingham AL - MD (Doctor of Medicine)
Specialties:
Neuropathology
Address:
UAB Department Of Pathology
619 19Th St S, Birmingham 35249
(205) 934-4303 (Phone)
619 19Th St S, Birmingham 35249
(205) 934-4303 (Phone)
Languages:
English
Hospitals:
UAB Department Of Pathology
619 19Th St S, Birmingham 35249
University of Alabama Hospital
1802 6Th Ave South, Birmingham 35233
619 19Th St S, Birmingham 35249
University of Alabama Hospital
1802 6Th Ave South, Birmingham 35233
Education:
Medical School
Stanford University School Of Medicine
Graduated: 1985
Barnes Jewish Hospital S Campus
Stanford University School Of Medicine
Graduated: 1985
Barnes Jewish Hospital S Campus
Prevention Of Neurodegeneration By Macrolide Antibiotics
Prevention Of Neurodegeneration By Macrolide Antibiotics
US Patent:
2008022, Sep 11, 2008
Filed:
Aug 14, 2006
Appl. No.:
12/063715
Inventors:
John J. Shacka - Birmingham AL, US
Kevin A. Roth - Birmingham AL, US
Kevin A. Roth - Birmingham AL, US
International Classification:
A61K 31/335, A61K 31/47, A61K 31/4375, A61P 25/00
US Classification:
514300, 514450, 514313
Abstract:
The present disclosure describes the use of macrolide antibiotics to prevent neurodegeneration and to treat or prevent disease and conditions which involve neurodegeneration. While not being limited to a specific mechanism of action, in one embodiment, the macrolide antibiotics inhibit neurodegeneration caused by lysosomal and/or mitochondrial dysfunction. The present disclosure contemplates the use of any macrolide antibiotic and pharmaceutically acceptable derivatives thereof. In a specific embodiment, the macrolide antibiotics include bafilomycin A1, bafilomycin B1 and concanamycin.
Cathepsin-D Neuroprotection
Cathepsin-D Neuroprotection
US Patent:
2011006, Mar 17, 2011
Filed:
Jul 2, 2008
Appl. No.:
12/667832
Inventors:
Jianhua Zhang - Birmingham AL, US
Guy Caldwell - Northport AL, US
Kevin Roth - Birmingham AL, US
David Standaert - Birmingham AL, US
Kim Cladwell - Northport AL, US
Shusei Hamamichi - Tuscaloosa AL, US
Guy Caldwell - Northport AL, US
Kevin Roth - Birmingham AL, US
David Standaert - Birmingham AL, US
Kim Cladwell - Northport AL, US
Shusei Hamamichi - Tuscaloosa AL, US
Assignee:
THE UAB RESEARCH FOUNDATION - Birmingham AL
THE UNIVERSITY OF ALABAMA - Tuscaloosa AL
THE UNIVERSITY OF ALABAMA - Tuscaloosa AL
International Classification:
A61K 39/395, C12Q 1/37, A61K 38/02, A61P 25/28, A61P 25/16, A61K 31/7088, C12Q 1/68, A61K 38/48
US Classification:
4241301, 435 23, 514 178, 514 44 R, 435 6, 424 9466, 514 177
Abstract:
Provided herein are methods and compositions for promoting neuroprotection in a subject and for treating a neural disorder associated with protein aggregation comprising administering to the subject an agent that increases expression or activity of cathepsin-D. Also provided are methods of screening for agents that increase expression or activity of cathepsin-D and methods of screening for neuroprotective agents.